Fibroblast, Fibroblast-like Cell Or Derivative (e.g., Nih 3t3, Etc.) Patents (Class 435/357)
-
Publication number: 20120142595Abstract: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.Type: ApplicationFiled: October 20, 2011Publication date: June 7, 2012Applicant: Araim Pharmaceuticals, Inc.Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
-
Publication number: 20120142057Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.Type: ApplicationFiled: February 8, 2012Publication date: June 7, 2012Inventors: Hisahiro Tabuchi, Satoshi Tainaka, Tomoya Sugiyama
-
Publication number: 20120135020Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: ApplicationFiled: May 10, 2010Publication date: May 31, 2012Applicant: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Wantanabe
-
Publication number: 20120134972Abstract: The present invention provides isolated polypeptides comprising a fragment of the amino acid sequence of SEQ ID NO:1, or a variant, derivative or fusion thereof, which is capable of binding specifically to and lysing cells of Clostridium difficile, wherein the polypeptide exhibits greater lytic activity on cells of Clostridium difficile than the polypeptide of SEQ ID NO: 1. The invention further provides means for producing the same, methods for killing bacterial cells such as cells of Clostridium difficile, as well as methods for diagnosing, treating and preventing diseases and conditions associated with infection of the same.Type: ApplicationFiled: May 26, 2010Publication date: May 31, 2012Applicant: PLANT BIOSCIENCE LIMITEDInventors: Melinda Mayer, Arjan Narbad
-
Publication number: 20120129218Abstract: The present invention relates to a host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence. The host cell may further comprise a nucleic acid encoding a recombinant protein. The present invention also relates to a method for producing a recombinant protein by the host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence.Type: ApplicationFiled: November 11, 2011Publication date: May 24, 2012Applicant: UNIVERSITY OF DELAWAREInventors: KELVIN H. LEE, STEPHANIE HAMMOND
-
Publication number: 20120131697Abstract: The present invention pertains to an auxin receptor protein involved in activation of proton pump in plasma membrane of a plant derived from rice, a gene encoding the protein, a recombinant vector comprising the gene, a host cell transformed with the recombinant vector, a method of improving traits of a plant by transforming the plant with the recombinant plant expression vector, a plant having improved traits by transformation with the recombinant plant expression vector and seeds of the plant, and a composition comprising the gene of the invention for improving traits of a plant.Type: ApplicationFiled: July 21, 2010Publication date: May 24, 2012Applicant: REPUBLIC OF KOREA (MANAGEMENT: RURAL DEVELOPMENT ADMINSTRATION)Inventors: Dong Hern Kim, Keun Pyo Lee, Myong Il Kim, Yu Jin Kwon, Yong Sam Kim
-
Publication number: 20120108464Abstract: The present invention relates to a method of identifying a substance altering glucose uptake and/or GLUT4 translocation to the plasma membrane of a cell comprising contacting a test system comprising AKT substrate 160 kDa-protein (AS160-protein) with a test substance, and identifying a test substance as a substance altering glucose uptake of a cell by detecting a signal indicative for altered glucose uptake of a cell; a test system comprising a gene coding for the AKT substrate 160 kDa-protein (AS160-protein) and an inducible promoter providing for controllable expression of the gene; the use of the test system for the identification of a substance improving glucose uptake and/or GLUT4 translocation to the plasma membrane of a cell; and the use of AS 160-protein in a model for type 2 diabetes.Type: ApplicationFiled: January 27, 2010Publication date: May 3, 2012Applicant: SANOFI-AVENTISInventors: Norbert Tennagels, Daniela Baus, Kathrin Heermeier, Stefan Welte
-
Publication number: 20120107333Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 35, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.Type: ApplicationFiled: March 1, 2010Publication date: May 3, 2012Applicant: Oncotherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20120093845Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.Type: ApplicationFiled: March 15, 2010Publication date: April 19, 2012Applicant: Oncotherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa watanabe, Yusuke Nakamura, Yoichi Furukawa
-
Publication number: 20120083442Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 2, 2011Publication date: April 5, 2012Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Publication number: 20120082622Abstract: Isolated polynucleotides encoding Macaca fascicularis CCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.Type: ApplicationFiled: September 26, 2011Publication date: April 5, 2012Inventors: Michael Naso, Mary Ryan, Sandra Santulli-Marotto, Bethany Swencki-Underwood
-
Publication number: 20120077706Abstract: The invention relates to a method for determining if a test compound, or a mix of compounds, modulates the interaction between two proteins of interest. The determination is made possible via the use of two recombinant molecules, one of which contains the first protein a cleavage site for a proteolytic molecules, and an activator of a gene. The second recombinant molecule includes the second protein and the proteolytic molecule. If the test compound binds to the first protein, a reaction is initiated whereby the activator is cleaved, and activates a reporter gene.Type: ApplicationFiled: August 18, 2011Publication date: March 29, 2012Applicant: Life Technologies CorporationInventors: Kevin J. LEE, Richard Axel, Walter Strapps, Gilad Barnea
-
Publication number: 20120070868Abstract: Recombinant microbial cells are provided which have been engineered to produce fatty acid derivatives having linear chains containing an odd number of carbon atoms by the fatty acid biosynthetic pathway. Also provided are methods of making odd chain fatty acid derivatives using the recombinant microbial cells, and compositions comprising odd chain fatty acid derivatives produced by such methods.Type: ApplicationFiled: September 14, 2011Publication date: March 22, 2012Applicant: LS9, INC.Inventors: Grace J. Lee, John R. Haliburton, Zhihao Hu, Andreas W. Schirmer
-
Publication number: 20120070857Abstract: In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans.Type: ApplicationFiled: August 10, 2011Publication date: March 22, 2012Applicant: Senomyx IncInventors: Guy Servant, Hong Chang, Cyril Redcrow, Sumita Ray, Imran Clark, Bryan Moyer
-
Publication number: 20120064604Abstract: The present invention provides methods for producing retroviruses or viral vectors with enhanced infectivity. The methods entail transfecting a retroviral vector into a packaging cell that has suppressed expression or inhibited enzymatic activity of a parvulin prolyl peptidyl isomerase (parvulin PPIase), and culturing the transfected packaging cell to allow production of viral particles. The invention also provides methods for enhancing efficiency of gene transfer with a recombinant retrovirus. These methods involve constructing a recombinant retroviral vector expressing a target gene, transfecting into a packaging cell that has suppressed expression or inhibited enzymatic activity of a parvulin prolyl peptidyl isomerase (parvulin PPIase), culturing the transfected packaging cell to allow production of recombinant retroviral particles, harvesting recombinant retroviral particles from supernatant of the cultured cell, and transducing the recombinant retroviral particles into a target cell.Type: ApplicationFiled: May 18, 2010Publication date: March 15, 2012Inventor: Andrew Saphire
-
Publication number: 20120064622Abstract: The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest.Type: ApplicationFiled: October 31, 2011Publication date: March 15, 2012Applicant: GINKGO BIOWORKSInventors: CURT R. FISCHER, AUSTIN J. CHE, RESHMA P. SHETTY, JASON R. KELLY
-
Publication number: 20120058917Abstract: The invention relates to a nucleic acid comprising the following contiguous elements arranged in the 5 prime to 3 prime direction; a promoter; a selectable marker; a cloning site for receipt of a nucleic acid segment, said segment comprising a candidate miRNA target sequence; and a poly adenylation signal, said elements arranged such that a transcript directed by said promoter comprises said selectable marker, said candidate miRNA target sequence, and said poly adenylation signal in that order. Suitably the miRNA test sequence is or is derived from a 3?UTR. The invention also relates to methods for making and screening libraries.Type: ApplicationFiled: April 4, 2008Publication date: March 8, 2012Applicant: KING'S COLLEGE LONDONInventors: Johannes Adrianus Gaken, Azim Mohamedali
-
Publication number: 20120053232Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: March 1, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120039923Abstract: The present invention relates to modified HIV-1 envelope proteins where one or more N-glycosylation sites have been deleted or modified, which produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these proteins. The invention also provides for nucleic acids, vectors, antibodies and pharmaceutical compositions that comprise said modified HIV-1 envelope proteins.Type: ApplicationFiled: September 9, 2005Publication date: February 16, 2012Applicant: THE HENRY M. JACKSON FOUNDATIONInventors: Christopher Broder, Gerald Quinnan
-
Publication number: 20120039919Abstract: As described below, the present invention features compositions and methods featuring Pdx-1 polypeptides and fragments thereof for the diagnosis, prevention and treatment of diabetes.Type: ApplicationFiled: August 5, 2011Publication date: February 16, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Lijun Yang, Vijay Koya, Shi-Wu Li
-
Publication number: 20120034675Abstract: The present invention describes a novel tyrosinase protein and methods of use thereof. Specifically, the invention provides tyrosinase derived peptides and polynucleotides, and their ability to elicit an immune response and treat a melanoma.Type: ApplicationFiled: July 22, 2011Publication date: February 9, 2012Inventors: Stefana M. Petrescu, Costin I. Popescu, Raymond A. Dwek
-
Publication number: 20120021509Abstract: The present invention relates to a method for isolating pluripotent/multipotent stem cells derived from umbilical cord blood, characterized by culturing monocytes isolated from umbilical cord blood in a culture vessel containing fibronectin and then harvesting stem cells from the culture, the umbilical cord blood-derived pluripotent/multipotent stem cells isolated thereby; and a cell therapeutic agent containing the pluripotent/multipotent stem cells derived from umbilical cord blood or cells differentiated therefrom. The present invention also relates to a novel culture media for stem cells, a culture method for stem cells which is characterized by culturing and proliferating stem cells in the culture media, and a method for increasing stemness of stem cells which is characterized by a sphere culture or a three-dimensional culture of stem cells.Type: ApplicationFiled: March 3, 2010Publication date: January 26, 2012Applicant: SNU R&DB FOUNDATIONInventors: Kyung Sun Kang, Kyoung Hwan Roh
-
Publication number: 20120020940Abstract: The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity.Type: ApplicationFiled: September 24, 2009Publication date: January 26, 2012Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)Inventors: Jörg Durner, Christian Lindermayr, Ruth Brack-Werner
-
Publication number: 20120015042Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: January 18, 2011Publication date: January 19, 2012Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20120015841Abstract: The invention relates to novel cells and cell lines, and methods for making and using them.Type: ApplicationFiled: February 1, 2010Publication date: January 19, 2012Applicant: CHROMOCELL CORPORATIONInventors: Kambiz Shekdar, Dennis Sawchuk, Purvi Manoj Shah
-
Publication number: 20120016008Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human ribosomal protein L26 (RIBO26) and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: January 19, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120016006Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Systemic RNA Interference Defective-1 (SID-I) gene, and methods of using the dsRNA to inhibit expression of SID-1.Type: ApplicationFiled: November 17, 2009Publication date: January 19, 2012Inventors: Gregory Hinkle, Yosef Landesman
-
Publication number: 20120015840Abstract: The present invention relates to a method for generating an RNA library or a (poly)peptide library comprising the steps of: (a) providing one or more nucleic acid molecules each comprising i) two or more coding elements (A) each giving rise to an RNA molecule upon transcription and/or a (poly)peptide upon transcription and translation; and ii) linking elements (B) arranged according to the general formula of B(AB)2+n, wherein said linking elements comprise one or more sequence motifs not found in said two or more coding elements allowing specific disruption of the linking elements (B); (b) cloning the nucleic acid molecule of step (a) into a vector; (c) transforming a host cell with the vector obtained in step (b) and propagating said transformed cell; (d) preparing vector DNA from the transformed and propagated cells of step (c); (e) (i) disrupting the vector DNA obtained in step (d) with one or more agents recognizing said one or more sequence motifs of the linking elements or (ii) performing an amplificatiType: ApplicationFiled: January 22, 2010Publication date: January 19, 2012Inventor: Michael Lebens
-
Publication number: 20120014996Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers.Type: ApplicationFiled: June 24, 2011Publication date: January 19, 2012Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
-
Publication number: 20120010268Abstract: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 encoding HASH2 and methods of use.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010270Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010269Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human SMS3 (SMS3) and methods of use.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010275Abstract: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 and methods of use.Type: ApplicationFiled: September 18, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120004172Abstract: Disclosed herein is a method for determining a kinase activity of ERK for CDCA5 and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer or esophageal cancer that use or include such modulators.Type: ApplicationFiled: August 24, 2009Publication date: January 5, 2012Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Takuya Tsunoda
-
Publication number: 20120003266Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.Type: ApplicationFiled: November 24, 2009Publication date: January 5, 2012Applicant: The United States of America,as represented by The Secretary, National Institues of HealthInventors: Gary J. Nable, Wataru Akahata, Srinivas Rao
-
Publication number: 20110318808Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: April 14, 2011Publication date: December 29, 2011Inventors: Ellen Chi, Michael Hunter, Ronald Swanson
-
Publication number: 20110319286Abstract: The present invention identifies a method for investigating the response of a cell membrane-associated protein in a living cell to a drug by labeling the protein with a visual marker, and also selectively labeling the membrane portion of the protein with another visual marker, such that upon exposure of the cell to a stimulus, the translocation of the cell membrane-associated protein may be observed directly.Type: ApplicationFiled: December 29, 2009Publication date: December 29, 2011Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Yu Wang, Andrew P. McMahon
-
Publication number: 20110312088Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.Type: ApplicationFiled: May 17, 2011Publication date: December 22, 2011Applicant: Seattle Genetics, Inc.Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter, Hans Peter Gerber, Leigh Francisco
-
Publication number: 20110312514Abstract: The present invention discloses methods for detecting exposure of a living subject to genotoxic agents, testing sensitivity to a genotoxic agent, and determining DNA damage caused by exposure to an agent, comprising detecting the presence of FANCD2-containing foci from a sample collected from said subject. The presence of concentrated foci is indicative of DNA damage, and the degree of foci formation is correlated with degree of exposure. Diagnostic reagents contain a ligand that binds to human FANCD2 associated with a detectable label. Kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. The invention further discloses methods for identifying agents which modulate the ability of FANCD2-containing foci to form. Among other things, such agents are potentially useful chemosensitizing agents or may confer protection against damage caused by genotoxic agents.Type: ApplicationFiled: February 8, 2011Publication date: December 22, 2011Applicant: Dana-Farber Cancer Institute, Inc.Inventor: Alan D. D'Andrea
-
Publication number: 20110305718Abstract: Polypeptide sequences for inducing recombinant protein bodies are described. The sequences comprise a polyproline II (PPII) structure and/or a proline-rich sequence between two cysteine residues on either end. Recombinant protein bodies are useful for protein production because they allow for simple and efficient purification of high quantities of recombinant protein. In addition, other methods of using recombinant protein bodies, for example, in vaccination and food products, are also described.Type: ApplicationFiled: May 31, 2011Publication date: December 15, 2011Inventors: Maria Dolores Ludevid Múgica, Maria Immaculada Llop Tous, Pablo Marzábal Luna, Minu Joseph, Blanca Llompart Royo, Margarita Torrent Quetglas, Miriam Bastida Virgili
-
Publication number: 20110306090Abstract: The present invention describes new mammalian expression vectors comprising a novel combination of regulatory elements and one or more selection marker gene(s). The vector allows for incorporation of at least one, preferably two or more genes of interest, its/their subsequent expression, and for selection of transfected cells using, e.g., G418 and/or MTX. The pDGP?GOI vector as an example for a mammalian expression vector according to the present invention exhibits a 9555 bp sequence, one strand of which is represented by SEQ ID NO:2.Type: ApplicationFiled: December 18, 2009Publication date: December 15, 2011Applicant: LEK PHARMACEUTICALS D.D.Inventors: Andrej Francky, Dominik Gaser
-
Publication number: 20110294162Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: May 20, 2010Publication date: December 1, 2011Inventors: Glen E. Mikesell, Henry Shen, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach
-
Publication number: 20110294983Abstract: The present invention relates to single-chain proteins of the formula HRS1-L1-HRS2-L2-HRS3, wherein HRS1, HRS2 and HRS3 are heptad repeat sequences and L1 and L2 are structurally flexible linker sequences, and wherein HRS1, HRS2 and HRS3 form a thermodynamically stable triple-stranded, antiparallel, alpha-helical coiled coil structure in aqueous solution. The invention also relates to amino acid sequence variants, conditions and methods to obtain such proteins and variants, and us ages thereof, especially their usage as scaffolds and as therapeutic products.Type: ApplicationFiled: December 8, 2009Publication date: December 1, 2011Applicant: Complix NVInventors: Johan Desmet, Ignace Joseph Isabella Lasters, Stefan Loverix
-
Publication number: 20110294748Abstract: The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: May 25, 2011Publication date: December 1, 2011Inventors: Michael Diem, Karyn O'Neil
-
Publication number: 20110287483Abstract: Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Inventors: Christopher K. CROWELL, Gustavo E. GRAMPP
-
Publication number: 20110281803Abstract: An isolated polypeptide inhibitor of SuIfIa having a sequence which is a variant of Sulf1a, and which lacks sulfatase activity and lacks the ability to bind to the surface of a cell. The polypeptide inhibitor of SuIf1a may be the alternatively spliced isoform SuIf1b. An isolated polypeptide inhibitor of Sulf2a having a sequence which is a variant of Sulf2a, and which lacks sulfatase activity and lacks the ability to bind to the surface of a cell. The polypeptide inhibitor of Sulf2a may be the alternatively spliced isoform Sulf2b. A method of combating a cancer in which Wnt signalling is upregulated or of treating ischaemia in a patient, the method comprising administering to the patient a polypeptide inhibitor of Sulf1a and/or Sulf2a. A method of combating a cancer in which Wnt signalling is not upregulated, the method comprising administering to the patient an inhibitor of Sulf1b and/or Sulf2b.Type: ApplicationFiled: November 10, 2008Publication date: November 17, 2011Inventor: Gurtej Kaur Dhoot
-
Publication number: 20110262591Abstract: The present invention relates to novel polynucleotide sequences comprising genes that encode novel lipolytic enzymes, as well asfunctional equivalents of the gene or the amino acid sequences with high homology thereto. The invention also relates to methods of using these lipolytic enzymes in industrial processes, for example in the dairy or baking industry.Type: ApplicationFiled: February 26, 2009Publication date: October 27, 2011Inventors: Jan Metske Laan Van Der, Yulia M. Efimova, Karin Turk, Albertus Alard Van Dijk, Natalja Alekseevna Cyplenkova, Margot Elisabeth Francoise Schooneveld-Bergmans, Arie Gerrit Terdu, Arjen Sein
-
Publication number: 20110263585Abstract: The present invention relates to polypeptides, preferably from Drosophila melanogaster (DmShaI) as target for insecticides.Type: ApplicationFiled: November 5, 2009Publication date: October 27, 2011Applicant: BASF SEInventors: Paul Bernasconi, John Dorsch, Lynn Stam, Scott Zitko, Nancy B. Rankl, Mike Griswold, Franz-Josef Braun, Gang Lu, Robert D. Kirkton, Barbara Wedel, Joachim Dickhaut, Angela Hofhine, Jennifer Zink, Fae Malone, Daniel Houtz, Steffen Gross, Ramani Kandasamy, Damian London, Thomas M. Gurganus
-
Publication number: 20110250684Abstract: In order to provide a method for producing neural stem cells easily and quickly by inducing differentiation of somatic cells directly into neurospheres, dedifferentiation factors are introduced into somatic cells, which are then cultured in suspension in the presence of growth factors to produce the neurospheres, thereby allowing the neural stem cells to be produced quickly without establishing iPS cells.Type: ApplicationFiled: November 4, 2009Publication date: October 13, 2011Applicant: KEIO UNIVERSITYInventors: Wado Akamatsu, Hideyuki Okano
-
Publication number: 20110243898Abstract: Provided are methods for producing a reprogrammed fibroblast. The methods can include growing a plurality of fibroblasts in monolayer culture to confluency; and disrupting the monolayer culture to place at least a fraction of the plurality of fibroblasts into suspension culture under conditions sufficient to form one or more embryoid body-like spheres, wherein the one or more embryoid body-like spheres comprise one or more reprogrammed fibroblasts that express one or more markers not expressed by a fibroblast growing in the monolayer culture prior to the disrupting step. Also provided are reprogrammed fibroblasts produced by the disclosed methods, formulations that include reprogrammed fibroblasts, and methods for treating an injury to a tissue in a subject by administering to a subject in need thereof a composition of reprogrammed fibroblast cells in a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 22, 2010Publication date: October 6, 2011Applicant: The University of Louisville Research Foundation, Inc.Inventors: Douglas Dean, Yongqing Liu